1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,226 | 0,230 | 17:33 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.08. | Boule Diagnostics AB: Bulletin from the Extraordinary General Meeting August 31, 2026 in Boule Diagnostics | 208 | GlobeNewswire (Europe) | The Extraordinary General Meeting (the "EGM") resolved to approve a loan from one of the company's major shareholders, AB Grenspecialisten, in accordance with the Board of Directors' proposal. Complete... ► Artikel lesen | |
| 17.07. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q2 2026 | 165 | GlobeNewswire (Europe) | Quarter April-June 2026Net sales amounted to SEK 112.2 million (129.3), corresponding to a decrease of 13.3 percent. Organic sales growth amounted to -5.3 percent, currency effects amounted to -8.0... ► Artikel lesen | |
| 18.06. | Boule Diagnostics AB: Boule Diagnostics appoints new Chief Executive Officer | 670 | GlobeNewswire (Europe) | The Board of Directors at Boule Diagnostics has today appointed Johan Folkunger, Chief Executive Officer, effective June 22, 2026. Johan Folkunger succeeds Simonetta Tumbiolo, who has been serving... ► Artikel lesen | |
| 29.05. | Boule Diagnostics AB: Interim CEO at Boule Diagnostics | 175 | GlobeNewswire (Europe) | The board of directors at Boule Diagnostics has today appointed Simonetta Tumbiolo, currently Chief Commercial Officer Diagnostic, as Interim Chief Executive Officer, effective June 1 2026. As previously... ► Artikel lesen | |
| 13.05. | Boule Diagnostics AB: Bulletin from the Annual General Meeting May 13, 2026 in Boule Diagnostics | 302 | GlobeNewswire (Europe) | At the Annual General Meeting 2026 (the "AGM") it was resolved to adopt the balance sheets and profit and loss statements for the parent company and the group for the financial year 2025. The AGM resolved... ► Artikel lesen | |
| 28.04. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q1 2026 | 188 | GlobeNewswire (Europe) | Stable start to 2026
Quarter January-March 2026} Net sales amounted to SEK 101.6 million (112.9), corresponding to a decrease of 10.0 percent. Organic sales growth amounted to 3.0 percent, currency... ► Artikel lesen | |
| BOULE DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 11.02. | Boule Diagnostics AB: Boule Diagnostics Year-end report 2025 | 396 | GlobeNewswire (Europe) | Improved operating cash flowQuarter October-December 2025Net sales amounted to SEK 120.2 million (143.2), corresponding to a decrease of 16.0 percent. Organic sales growth amounted to -11.7 percent... ► Artikel lesen | |
| 30.12.25 | Boule Diagnostics AB: Boule Diagnostics appoints Michael af Winklerfelt as new CFO | 373 | GlobeNewswire (Europe) | Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals... ► Artikel lesen | |
| 22.12.25 | Boule Diagnostics AB: Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy | 201 | GlobeNewswire (Europe) | Boule Diagnostics, together with its Italian distribution partner A. Menarini Diagnostics, is proud to announce its selection as one of only three providers in a nationwide tender for hematology solutions... ► Artikel lesen | |
| 05.12.25 | Boule Diagnostics AB: Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter | 231 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Torben Nielsen, Chief Executive Officer, has decided to leave the company to pursue another professional opportunity. Under Torben's leadership, the company has... ► Artikel lesen | |
| 24.10.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q3 2025 | 301 | GlobeNewswire (Europe) | Back to organic growth Quarter July-September 2025Net sales amounted to SEK 127.2 million (130.4), corresponding to a decrease of 2.4 percent. Organic sales growth amounted to 1.7 percent, currency... ► Artikel lesen | |
| 13.10.25 | Boule Diagnostics AB: Boule Diagnostics Announces CFO Departure for New Opportunity | 224 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Holger Lembrér, Chief Financial Officer, will be leaving the company to pursue a new professional opportunity outside the organization.Torben Nielsen, CEO of Boule... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AETHLON MEDICAL | 7,020 | +390,91 % | Morning Market Movers: Aethlon Medical, CID HoldCo, Longeveron, Delixy See Big Swings | OTTAWA (dpa-AFX) - At 8:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 38,950 | -2,70 % | EQS-PVR: Fresenius Medical Care AG: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG | EQS Stimmrechtsmitteilung: Fresenius Medical Care AG
Fresenius Medical Care AG: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG
10.09.2026... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 9,240 | +6,08 % | Alignment Healthcare extends retreat, falls an additional 16% | ||
| FRESENIUS | 45,905 | -0,51 % | EQS-DD: Fresenius SE & Co. KGaA: Sara Hennicken, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
10.09.2026 / 11:59... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,510 | +0,39 % | BERENBERG stuft Siemens Healthineers auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Siemens Healthineers mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv... ► Artikel lesen | |
| BETA BIONICS | 21,050 | -5,09 % | Beta Bionics, Inc.: Beta Bionics Announces FDA Clearance of Mint, the Company's Transformative Patch Pump, and Unveils 3D Intelligence as its Next-Generation Insulin Dosing Algorithm | Mint features a new and innovative patch pump architecture Full Mint U.S. commercialization expected to begin in Q1 2027 Manufacturing capacity expected to produce at least 1.5 million disposable... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 58,95 | -0,02 % | Here's Why You Should Add BrightSpring Stock to Your Portfolio Now | ||
| GENEDX | 102,02 | +4,66 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| CARL ZEISS MEDITEC | 29,300 | -3,30 % | EQS-DD: Carl Zeiss Meditec AG: Andreas Pecher, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
10.09.2026 / 15:20... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 14,110 | -1,05 % | Aveanna Healthcare auf dem Deutsche Bank Healthcare Summit 2026: Neuausrichtung auf Wachstumskurs | ||
| LIFESTANCE HEALTH GROUP | 12,945 | 0,00 % | LifeStance Health auf Morgan Stanley Konferenz: Wachstum und Margen im Fokus | ||
| ESSILORLUXOTTICA | 141,40 | -2,78 % | Wie kommt eine neue Brillentechnologie in einen 160-Milliarden-Dollar-Markt? Warum Vertrieb für kleine Health-Tech-Unternehmen zum entscheidenden Faktor wird | ||
| HEARTFLOW | 49,140 | +1,68 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| NUWELLIS, INC | 1,010 | +23,93 % | Nuwellis, Inc.: Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs | MINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced... ► Artikel lesen | |
| BILLIONTOONE | 107,95 | +4,29 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen |
Das Unternehmen BOULE DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,72 % bei einem Aktienkurs von 0,228 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOULE DIAGNOSTICS AB finden Sie auf Wallstreet Online.